keyword
MENU ▼
Read by QxMD icon Read
search

Fibrates

keyword
https://www.readbyqxmd.com/read/29662003/ppar-agonists-and-metabolic-syndrome-an-established-role
#1
REVIEW
Margherita Botta, Matteo Audano, Amirhossein Sahebkar, Cesare R Sirtori, Nico Mitro, Massimiliano Ruscica
Therapeutic approaches to metabolic syndrome (MetS) are numerous and may target lipoproteins, blood pressure or anthropometric indices. Peroxisome proliferator-activated receptors (PPARs) are involved in the metabolic regulation of lipid and lipoprotein levels, i.e., triglycerides (TGs), blood glucose, and abdominal adiposity. PPARs may be classified into the α, β/δ and γ subtypes. The PPAR-α agonists, mainly fibrates (including newer molecules such as pemafibrate) and omega-3 fatty acids, are powerful TG-lowering agents...
April 14, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29659082/is-hepatic-peroxisome-proliferator-activated-receptor-%C3%AE-essential-for-the-metabolic-effects-of-fibrates
#2
EDITORIAL
Y Kamijo
No abstract text is available yet for this article.
May 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29628329/structure-guided-evolution-of-a-2-phenyl-4-carboxyquinoline-chemotype-into-ppar%C3%AE-selective-agonists-new-leads-for-oculovascular-conditions
#3
Xiao-Zheng Dou, Dinesh Nath, Younghwa Shin, Jian-Xing Ma, Adam S Duerfeldt
Small molecule agonism of PPARα represents a promising new avenue for the development of non-invasive treatments for oculovascular diseases like diabetic retinopathy and age-related macular degeneration. Herein we report initial structure-activity relationships for the newly identified quinoline-based PPARα agonist, Y-0452. Preliminary computational studies led to the hypothesis that carboxylic acid transposition and deconstruction of the Y-0452 quinoline system would enhance ligand-protein interactions and better complement the nature of the binding pocket...
April 5, 2018: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29620657/fenofibrate-monotherapy-induced-rhabdomyolysis-in-a-patient-with-hypothyroidism-a-rare-case-report-and-literature-review
#4
Dawei Wang, Yanqiu Wang
RATIONALE: Fenofibrate is a fibric acid derivative indicated for use in hypertriglyceridemia and mixed dyslipidemia treatment among adults. Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release of intracellular muscle contents into the systemic circulation, which is the most serious and fatal side effect of fenofibrate. The objective of this paper is to discuss fatal side effect of fenofibrate and keep safe medication. PATIENT CONCERNS: A patient with hypothyroidism who presented with rhabdomyolysis during fenofibrate monotherapy for hypertriglyceridemia was reported...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29606790/magnetic-zero-modes-vortices-and-cartan-geometry
#5
Calum Ross, Bernd J Schroers
We exhibit a close relation between vortex configurations on the 2-sphere and magnetic zero-modes of the Dirac operator on [Formula: see text] which obey an additional nonlinear equation. We show that both are best understood in terms of the geometry induced on the 3-sphere via pull-back of the round geometry with bundle maps of the Hopf fibration. We use this viewpoint to deduce a manifestly smooth formula for square-integrable magnetic zero-modes in terms of two homogeneous polynomials in two complex variables...
2018: Letters in Mathematical Physics
https://www.readbyqxmd.com/read/29593789/drugs-involved-in-dyslipidemia-and-obesity-treatment-focus-on-adipose-tissue
#6
REVIEW
Sofia Dias, Sílvia Paredes, Laura Ribeiro
Metabolic syndrome can be defined as a state of disturbed metabolic homeostasis characterized by visceral obesity, atherogenic dyslipidemia, arterial hypertension, and insulin resistance. The growing prevalence of metabolic syndrome will certainly contribute to the burden of cardiovascular disease. Obesity and dyslipidemia are main features of metabolic syndrome, and both can present with adipose tissue dysfunction, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue...
2018: International Journal of Endocrinology
https://www.readbyqxmd.com/read/29578959/fibrates-in-hypertension-where-do-we-stand
#7
Hendrik Gremmels, Jaap A Joles
No abstract text is available yet for this article.
May 2018: Journal of Hypertension
https://www.readbyqxmd.com/read/29567478/molecular-association-model-of-ppar%C3%AE-and-its-new-specific-and-efficient-ligand-pemafibrate-structural-basis-for-spparm%C3%AE
#8
Yuta Yamamoto, Kenta Takei, Sundaram Arulmozhiraja, Vladimir Sladek, Naoya Matsuo, Son-Iee Han, Takashi Matsuzaka, Motohiro Sekiya, Takaki Tokiwa, Mitsuo Shoji, Yasuteru Shigeta, Yoshimi Nakagawa, Hiroaki Tokiwa, Hitoshi Shimano
Peroxisome proliferator-activated receptor-α (PPARα) is a ligand-activated transcription factor involved in the regulation of lipid homeostasis and improves hypertriglyceridemia. Pemafibrate is a novel selective PPARα modulator (SPPARMα) that activates PPARα transcriptional activity. Here, we computationally constructed the structure of the human PPARα in a complex with pemafibrate, along with that of hPPARα complexed with the classical fenofibrate, and studied their interactions quantitatively by using the first-principles calculations-based fragment molecular orbital (FMO) method...
March 19, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29559785/safety-of-high-dose-daptomycin-in-patients-with-severe-renal-impairment
#9
Chih-Hsun Tai, Chi-Hao Shao, Chen-You Chen, Shu-Wen Lin, Chien-Chih Wu
Background: Treatment options are limited for infections due to multidrug-resistant Gram-positive pathogens. Daptomycin is a lipopeptide antibiotic with concentration-dependent killing characteristic and dose-dependent post-antibiotic effect. To achieve optimized pharma-codynamic effect, some experts advocated using a high dose of daptomycin (≥9 mg/kg) for severe infections. However, the safety of high-dose therapy in patients with renal impairment remains unknown. This study was aimed to evaluate the safety of daptomycin in patients with severe renal impairment...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29526309/primary-biliary-cholangitis
#10
REVIEW
Albert Parés
Primary cholangitis (cirrhosis) is a chronic cholestatic disease with an unquestionable female predominance. It is characterised by inflammation of the small and medium size bile ducts, and can eventually progress to cirrhosis. Most patients remain asymptomatic and are diagnosed by the casual finding of an anicteric biochemical cholestasis with increased alkaline phosphatase. The pathogenesis is unknown and of presumed autoimmune origin in genetic susceptible subjects. M2-type antimitochondrial antibodies, and specific antinuclear antibodies (gp210 and Sp100) are typical and specific of the disease...
March 8, 2018: Medicina Clínica
https://www.readbyqxmd.com/read/29524177/components-of-metabolic-syndrome-in-relation-to-plasma-levels-of-retinol-binding-protein-4-rbp4-in-a-cohort-of-people-aged-65-years-and-older
#11
M Majerczyk, P Kocełak, P Choręza, H Arabzada, A J Owczarek, M Bożentowicz-Wikarek, A Brzozowska, A Szybalska, M Puzianowska-Kuźnicka, T Grodzicki, A Więcek, M Olszanecka-Glinianowicz, J Chudek
PURPOSE: Elevated plasma concentration of retinol binding protein 4 (RBP4) has recently emerged as a potential risk factor as a component of developing metabolic syndrome (MS). Therefore, this study aimed to analyse the relationship between components of MS and concentrations of plasma RBP4 in a population of subjects 65 years and older. METHODS: The study sample consisted of 3038 (1591 male) participants of the PolSenior study, aged 65 years and older. Serum lipid profile, concentrations of RBP4, glucose, insulin, C-reactive protein, IL-6, and activity of aminotransferases were measured...
March 9, 2018: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/29517392/evaluation-of-a-new-equation-for-ldl-c-estimation-and-prediction-of-death-by-cardiovascular-related-events-in-a-german-population-based-study-cohort
#12
Caio Mauricio Mendes de Cordova, Ernani Tiarajú de Santa Helena, Caroline Galgowski, Vitor Holmo Figueira, Gabrielle Bortoli Setter, Marcello Ricardo Paulista Markus, Carsten Oliver Schmidt, Henry Völzke, Till Ittermann
A simple equation established by Cordova & Cordova (LDL-COR) was developed to provide an improved estimation of LDL-cholesterol in a large Brazilian laboratory database. We evaluated this new equation in a general population cohort in Pomerania, north-eastern Germany (SHIP Study) compared to other existing formulas (Anandaraja, Teerakanchana, Chen, Hattori, Martin, Friedewald and Ahmadi), and its power in the prediction of death by atherosclerosis related events as the primary outcome. Analysis was conducted on a cohort of 4075 individuals considering age, gender, use of lipid lowering therapy and associated co-morbidities such as diabetes, hepatic, kidney and thyroid disease...
March 8, 2018: Scandinavian Journal of Clinical and Laboratory Investigation
https://www.readbyqxmd.com/read/29502862/peroxisome-proliferator-activated-receptor-gamma-coactivator-1-alpha-as-a-novel-target-for-bipolar-disorder-and-other-neuropsychiatric-disorders
#13
REVIEW
Andrew A Nierenberg, Sharmin A Ghaznavi, Isadora Sande Mathias, Kristen K Ellard, Jessica A Janos, Louisa G Sylvia
Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) is a protein that regulates metabolism and inflammation by activating nuclear receptors, especially the family of peroxisome proliferator-activated receptors (PPARs). PGC-1 alpha and PPARs also regulate mitochondrial biogenesis, cellular energy production, thermogenesis, and lipid metabolism. Brain energy metabolism may also be regulated in part by the interaction between PGC-1 alpha and PPARs. Because neurodegenerative diseases (Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis) and bipolar disorder have been associated with dysregulated mitochondrial and brain energy metabolism, PGC-1 alpha may represent a potential drug target for these conditions...
January 10, 2018: Biological Psychiatry
https://www.readbyqxmd.com/read/29493554/elevated-triglycerides-and-low-high-density-lipoprotein-cholesterol-level-as-marker-of-very-high-risk-in-type-2-diabetes
#14
Michel P Hermans, Paul Valensi
PURPOSE OF REVIEW: The aim of this review is to describe in diabetic patients the determinants underlying atherogenic dyslipidemia, a complex dyslipidemia defined as the coexistence of fasting hypertriglyceridemia and low high-density lipoprotein cholesterol level. Atherogenic dyslipidemia is often comorbid with hyperglycemia in patients with the common form of type 2 diabetes mellitus (T2DM), namely that associated with obesity, insulin resistance, hyperinsulinemia and the metabolic syndrome phenotype...
April 2018: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/29459241/the-atherogenic-dyslipidemia-complex-and-novel-approaches-to-cardiovascular-disease-prevention-in-diabetes
#15
REVIEW
Priska Stahel, Changting Xiao, Robert A Hegele, Gary F Lewis
Despite the effectiveness of low-density lipoprotein (LDL)-lowering strategies for the treatment of diabetic dyslipidemia, significant residual risk of atherosclerotic cardiovascular disease remains. Residual risk might in part be explained by lipid abnormalities that go beyond LDL cholesterol elevation, collectively termed the "atherogenic dyslipidemia complex (ADC)," consisting of hypertriglyceridemia, elevated small dense LDL particles, reduced high-density lipoprotein cholesterol, and high-density lipoprotein particle numbers, increased remnant lipoproteins, and postprandial hyperlipidemia...
December 15, 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/29424255/the-therapeutic-potential-of-cetp-inhibitors-a-patent-review
#16
Xinran Wang, Wei Li, Lijuan Hao, Honglei Xie, Chenzhou Hao, Chunchi Liu, Wenyan Li, Xuqiong Xiong, Dongmei Zhao
Epidemiological studies have identified that high levels of low-density lipoprotein-cholesterol (LDL-C) and low levels of high-density lipoprotein-cholesterol (HDL-C) are two independent causes of cardiovascular disease (CVD). Statins, niacin and fibrate are used for the treatment of CVD. However, some defects are shown in the treatment process. Thus, there is a demand for better treatment strategies that confer preferable efficacy with fewer side effects. Cholesteryl ester transfer protein (CETP) promotes the movement of CEs from HDL to LDL and VLDL in exchange for triglycerides (TGs)...
February 9, 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29413998/lipid-lowering-treatment-in-peripheral-artery-disease
#17
REVIEW
Niki Katsiki, Athanasios D Giannoukas, Vasilios G Athyros, Dimitri P Mikhailidis
Peripheral artery disease (PAD) is characterized by increased cardiovascular (CV) risk, limb morbidity and all-cause mortality. According to the current guidelines (2016) of the American Heart Association/American College of Cardiology on the management of PAD patients, statin therapy is recommended for PAD patients in order to treat dyslipidemia and reduce CV risk. The present narrative review discusses the use of statins and other lipid-lowering drugs such as ezetimibe, fibrates, niacin, anacetrapib and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in PAD patients in terms of both CV and limb outcomes...
January 31, 2018: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29395493/fibrates-in-the-secondary-prevention-of-cardiovascular-disease-infarction-and-stroke-results-of-a-systematic-review-and-meta-analysis-of-the-cochrane-collaboration
#18
Jesus Millan, Xavier Pintó, Angel Brea, Mariano Blasco, Antonio Hernandez Mijares, Juan Ascaso, Angel Diaz, Teresa Mantilla, Juan Pedro-Botet
Fibrates are a group of drugs that are known mainly for reducing triglycerides, increasing high density lipoproteins (HDL), and reducing the fraction of small, dense LDL particles. The results of a Cochrane Collaboration study have recently been published on their efficacy and safety in the secondary prevention of severe cardiovascular accidents, including coronary and cerebrovascular disease. The study included randomised clinical trials in which the fibrate was compared with placebo or with no treatment. Clinical trials comparing two different fibrates were excluded...
January 30, 2018: Clínica e Investigación en Arteriosclerosis
https://www.readbyqxmd.com/read/29381696/association-between-triglyceride-levels-and-cardiovascular-disease-in-patients-with-acute-pancreatitis
#19
Laurel A Copeland, C Scott Swendsen, Dawn M Sears, Andrea A MacCarthy, Catherine J McNeal
Conventional wisdom supports prescribing "fibrates before statins", that is, prioritizing treatment of hypertriglyceridemia (hTG) to prevent pancreatitis ahead of low-density lipoprotein cholesterol to prevent coronary heart disease. The relationship between hTG and acute pancreatitis, however, may not support this approach to clinical management. This study analyzed administrative data from the Veterans Health Administration for evidence of (1) temporal association between assessed triglycerides level and days to acute pancreatitis admission; (2) association between hTG and outcomes in the year after hospitalization for acute pancreatitis; (3) relative rates of prescription of fibrates vs statins in patients with acute pancreatitis; (4) association of prescription of fibrates alone versus fibrates with statins or statins alone with rates of adverse outcomes after hospitalization for acute pancreatitis...
2018: PloS One
https://www.readbyqxmd.com/read/29361723/treatment-strategy-for-dyslipidemia-in-cardiovascular-disease-prevention-focus-on-old-and-new-drugs
#20
Donatella Zodda, Rosario Giammona, Silvia Schifilliti
Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C). However, due to adherence to statin therapy or statin resistance, many patients do not reach LDL-C target levels. Ezetimibe, fibrates, and nicotinic acid represent the second-choice drugs to be used in combination with statins if lipid targets cannot be reached...
January 21, 2018: Pharmacy (Basel, Switzerland)
keyword
keyword
80664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"